News

Public · Published

Novartis lifts profit outlook as new medicines counter generic erosion

Novartis raised its full-year profit outlook after newer medicines offset generic competition for its heart drug Entresto. It now expects core operating income to be broadly flat or grow by a low single-digit percentage at constant currencies, reversing a previous forecast for a low single-digit decline.

Published:

Updated:

What happened

Novartis raised its full-year profit outlook after newer medicines offset generic competition for its heart drug Entresto. It now expects core operating income to be broadly flat or grow by a low single-digit percentage at constant currencies, reversing a previous forecast for a low single-digit decline.

Confirmed

Global impact / market context

Rising sales of newer drugs are replacing revenue lost as older medicines face cheaper copies, which supports profit. That lets Novartis spend on research and launches, and a higher profit outlook can support the share price and investor confidence.

Analyst inference

Drugmakers regularly lose sales when patents expire, so investors watch whether new products can replace that revenue. Novartis showed this replacement working, with strong growth in Kisqali, Kesimpta, Scemblix and Leqvio outweighing Entresto pressure and a large impairment charge.

Analyst inference

What to watch

  1. Novartis maintained its outlook for low single-digit sales growth at constant currencies, which means sales are expected to rise modestly after removing currency swings. Confirmed
  2. Watch whether Kisqali, Kesimpta, Scemblix and Leqvio keep growing fast enough to offset further generic competition for Entresto in coming quarters. Proposed
  3. The $1.9B impairment charge for del-desiran, a write-down of an experimental drug's value after a trial setback, may reduce reported profit even if core results stay strong. Analyst inference

Evidence